## The Preclinical MPT Pipeline by Indication Combination

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Delivery Method</th>
<th>Product Developer</th>
<th>Stage of Development</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HIV &amp; Pregnancy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiretroviral (ARV)/Levonorgestrel Long-Acting MPT Injectable</td>
<td>Injectable</td>
<td>CONRAD</td>
<td>Advanced Preclinical</td>
<td>HIV, Pregnancy</td>
</tr>
<tr>
<td>EfDA-P + Progestin Intravaginal Film</td>
<td>Vaginal Film</td>
<td>Magee-Women’s Research Inst. &amp; Fndn.</td>
<td>Early Preclinical</td>
<td>HIV, Pregnancy</td>
</tr>
<tr>
<td>Human Contraceptive Antibody (HCA) + VRC01 + N6 IVR</td>
<td>Intravaginal Ring (IVR)</td>
<td>MUCCOMMUNE LLC</td>
<td>Advanced Preclinical</td>
<td>HIV, Pregnancy</td>
</tr>
<tr>
<td>Islatravir (EfDA) + Etonogestrel/Ethinyl Estradiol 3D Printed IVR</td>
<td>Intravaginal Ring (IVR)</td>
<td>University of North Carolina, Chapel Hill</td>
<td>Early Preclinical</td>
<td>HIV, Pregnancy</td>
</tr>
<tr>
<td>MPT Microarray Patch</td>
<td>Microarray Patch</td>
<td>PATH</td>
<td>Early Preclinical</td>
<td>HIV, Pregnancy</td>
</tr>
<tr>
<td>90-day Pod-type Etonogestrel/Ethinyl Estradiol/QGriffithsin (EEQ) IVR</td>
<td>Intravaginal Ring (IVR)</td>
<td>Population Council</td>
<td>Early Preclinical</td>
<td>HIV, Pregnancy</td>
</tr>
<tr>
<td>Novel mAb contraceptive + Tenofovir Disoproxil Fumarate (TDF) IVR</td>
<td>Intravaginal Ring (IVR)</td>
<td>Oak Crest Institute of Science, Univ. of North Carolina, Chapel Hill</td>
<td>Early Preclinical</td>
<td>HIV, Pregnancy</td>
</tr>
<tr>
<td>Subcutaneous Contraceptive + HIV Implant Engineered for Long-Acting Delivery (SCHIELD) device</td>
<td>Implant</td>
<td>RTI</td>
<td>Early Preclinical</td>
<td>HIV, Pregnancy</td>
</tr>
<tr>
<td>Ultra-Long-Acting MPT In-situ Forming Implant (ISFI)</td>
<td>Injectable In-situ Forming Implant</td>
<td>University of North Carolina, Chapel Hill</td>
<td>Early Preclinical</td>
<td>HIV, Pregnancy</td>
</tr>
<tr>
<td><strong>HIV &amp; Other STIs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mAb 2C7 + TDF IVR</td>
<td>Intravaginal Ring (IVR)</td>
<td>MassBiologics, Oak Crest Institute of Science, Planet Biotechnology, Inc., University of Massachusetts</td>
<td>Advanced Preclinical</td>
<td>Gonorrhea, HIV</td>
</tr>
<tr>
<td>Tenofovir (TFV)/Efavirenz (EFV) Nanoparticles-in-film</td>
<td>Vaginal Film</td>
<td>Inst. For Research &amp; Innovation in Health (i3S), University of Porto</td>
<td>Advanced Preclinical</td>
<td>HIV, HSV-1, HSV-2</td>
</tr>
<tr>
<td>VivaGel® Vaginal Gel</td>
<td>Vaginal Gel</td>
<td>Starpharma Ltd.</td>
<td>Advanced Preclinical</td>
<td>BV, HIV, HPV, HSV-2</td>
</tr>
<tr>
<td><strong>Pregnancy, HIV, &amp; Other STIs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amphora/QGriffithsin (QGRFT) fast-dissolving vaginal insert (FDI)</td>
<td>Vaginal Insert</td>
<td>Evofem Biosciences, Inc., Population Council</td>
<td>Early Preclinical</td>
<td>BV, Chlamydia, Gonorrhea, HIV, Pregnancy</td>
</tr>
<tr>
<td>Dapivirine + Pritelivir + Levonorgestrel 3D Printed IVR</td>
<td>Intravaginal Ring (IVR)</td>
<td>University of North Carolina, Chapel Hill</td>
<td>Early Preclinical</td>
<td>HIV, HSV-2, Pregnancy</td>
</tr>
<tr>
<td>Dolutegravir + Rilpivirine + Acyclovir + Ethinyl Estradiol + Etonogestrel IVR</td>
<td>Intravaginal Ring (IVR)</td>
<td>Auritec Pharmaceuticals</td>
<td>Advanced Preclinical</td>
<td>HIV, HSV-2, Pregnancy</td>
</tr>
<tr>
<td>Yaso-GEL</td>
<td>Vaginal Gel</td>
<td>Yaso Therapeutics</td>
<td>Advanced Preclinical</td>
<td>Gonorrhea, HIV, HPV, HSV-2, Pregnancy</td>
</tr>
</tbody>
</table>

For more information visit MPTs101.org  
Updated October 2021
### Pregnancy & Non-HIV STIs

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Delivery Method</th>
<th>Product Developer</th>
<th>Clinical Phase</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphora fast-dissolving vaginal insert (FDI)</td>
<td>Vaginal Insert</td>
<td>Evofem Biosciences, Inc., Population Council</td>
<td>Early Preclinical</td>
<td>BV, Chlamydia, Gonorrhea, Pregnancy</td>
</tr>
<tr>
<td>Copper Intravaginal Ring (Cu-IVR)</td>
<td>Intravaginal Ring (IVR)</td>
<td>University of California, Davis</td>
<td>Early Preclinical</td>
<td>HSV-2, Zika virus, Pregnancy</td>
</tr>
</tbody>
</table>

### MPTs in Clinical Trials by Indication Combination

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Delivery Method</th>
<th>Product Developer</th>
<th>Clinical Phase</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV &amp; Pregnancy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dapivirine + Levonorgestrel IVR</td>
<td>Intravaginal Ring (IVR)</td>
<td>IPM</td>
<td>Phase 1 Clinical Trial</td>
<td>HIV, Pregnancy</td>
</tr>
<tr>
<td>Dual Prevention Pill (DPP) / TELE</td>
<td>Oral Pill</td>
<td>Viatris</td>
<td>Clinical - Bioequivalence Study</td>
<td>HIV, Pregnancy</td>
</tr>
<tr>
<td>HIV &amp; Other STIs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MIV-150 and zinc acetate in carrageenan gel (PC-1005)</td>
<td>Vaginal, Rectal Gel</td>
<td>Population Council</td>
<td>Phase 2 Clinical Trial</td>
<td>HIV, HPV, HSV-2</td>
</tr>
<tr>
<td>Q-Griffithsin (Q-GRFT) Enema</td>
<td>Enema</td>
<td>University of Louisville</td>
<td>Phase 1 Clinical Trial</td>
<td>Hepatitis C, HIV, HPV, HSV-2</td>
</tr>
<tr>
<td>Tenofovir Alafenamide (TAF) / Elvitegravir Topical Insert</td>
<td>Vaginal, Rectal Insert</td>
<td>CONRAD</td>
<td>Phase 1 Clinical Trial</td>
<td>HIV, HSV-2</td>
</tr>
<tr>
<td>Tenofovir IVR</td>
<td>Intravaginal Ring (IVR)</td>
<td>CONRAD</td>
<td>Phase 2 Clinical Trial</td>
<td>HIV, HSV-2</td>
</tr>
<tr>
<td>Pregnancy, HIV, &amp; Other STIs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tenofovir + Levonorgestrel IVR</td>
<td>Intravaginal Ring (IVR)</td>
<td>CONRAD</td>
<td>Phase 2 Clinical Trial</td>
<td>HIV, HSV-2, Pregnancy</td>
</tr>
<tr>
<td>Pregnancy &amp; Non-HIV STIs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVO100 Gel</td>
<td>Vaginal Gel</td>
<td>Evofem Biosciences, Inc.</td>
<td>Phase 3 Clinical Trial</td>
<td>Chlamydia, Gonorrhea, Pregnancy</td>
</tr>
</tbody>
</table>

To learn more about the MPT pipeline, check out the interactive online MPT Product Development Database at MPTs101.org